Scholarly Index
Alessandra Ferrajoli
The University of Texas MD Anderson Cancer Center; 27,918 total citations; 854 total publications; best world rank #88
The University of Texas MD Anderson Cancer Center
27,918Total citations
854Total publications
91H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia Research | Lifetime | 101 | US 61 | 99.66 |
| Lymphoma Diagnosis and Treatment | Lifetime | 129 | US 63 | 99.55 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 97 | US 46 | 99.43 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 157 | US 81 | 99.11 |
| Acute Lymphoblastic Leukemia research | Lifetime | 380 | US 196 | 98.54 |
| Acute Myeloid Leukemia Research | Lifetime | 579 | US 268 | 98.48 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 444 | US 196 | 96.86 |
| Advanced Breast Cancer Therapies | Lifetime | 392 | US 181 | 96.84 |
| Multiple Myeloma Research and Treatments | Lifetime | 696 | US 314 | 96.66 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 997 | US 520 | 93.35 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 88 | US 44 | 98.83 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 182 | US 94 | 98.03 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 197 | US 61 | 95.13 |
| Advanced Breast Cancer Therapies | 2021-2025 | 491 | US 176 | 91.01 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 790 | US 301 | 86.72 |